tryptophan has been researched along with Myelodysplastic Syndromes in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bassermann, F; Germing, U; Götze, KS; Heider, M; Kirchner, T; Müller-Thomas, C; Piontek, G; Rudelius, M; Schlensog, M | 1 |
| Allorge, D; Berthon, C; Briche, I; Corm, S; Fontenay, M; Hennart, B; Lhermitte, M; Quesnel, B | 1 |
1 trial(s) available for tryptophan and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Metabolites of tryptophan catabolism are elevated in sera of patients with myelodysplastic syndromes and inhibit hematopoietic progenitor amplification.
Topics: Adult; Cell Proliferation; Cells, Cultured; Female; Hematopoietic Stem Cells; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Male; Myelodysplastic Syndromes; Tryptophan; Tryptophan Oxygenase | 2013 |
1 other study(ies) available for tryptophan and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Prognostic value of indoleamine 2,3 dioxygenase in patients with higher-risk myelodysplastic syndromes treated with azacytidine.
Topics: Aged; Aged, 80 and over; Azacitidine; Biomarkers; Bone Marrow; CD8-Positive T-Lymphocytes; Cells, Cultured; Combined Modality Therapy; DNA Methylation; Drug Therapy, Combination; Enzyme Induction; Female; Hematopoietic Stem Cell Transplantation; Humans; Immune Checkpoint Inhibitors; Indoleamine-Pyrrole 2,3,-Dioxygenase; Macrophages; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Risk; Tryptophan | 2020 |